Literature DB >> 11364249

Nelfinavir (Viracept) approved: fourth protease inhibitor available.

J S James.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 11364249

Source DB:  PubMed          Journal:  AIDS Treat News        ISSN: 1052-4207


× No keyword cloud information.
  4 in total

1.  A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.

Authors:  Michelle Alonso-Basanta; Penny Fang; Amit Maity; Stephen M Hahn; Robert A Lustig; Jay F Dorsey
Journal:  J Neurooncol       Date:  2013-11-06       Impact factor: 4.130

2.  Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

Authors:  Joong Sup Shim; Rajini Rao; Kristin Beebe; Len Neckers; Inkyu Han; Rita Nahta; Jun O Liu
Journal:  J Natl Cancer Inst       Date:  2012-10-05       Impact factor: 13.506

Review 3.  The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.

Authors:  Michael A Serwetnyk; Brian S J Blagg
Journal:  Acta Pharm Sin B       Date:  2020-11-24       Impact factor: 11.413

Review 4.  Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

Authors:  Usman Arshad; Henry Pertinez; Helen Box; Lee Tatham; Rajith K R Rajoli; Paul Curley; Megan Neary; Joanne Sharp; Neill J Liptrott; Anthony Valentijn; Christopher David; Steve P Rannard; Paul M O'Neill; Ghaith Aljayyoussi; Shaun H Pennington; Stephen A Ward; Andrew Hill; David J Back; Saye H Khoo; Patrick G Bray; Giancarlo A Biagini; Andrew Owen
Journal:  Clin Pharmacol Ther       Date:  2020-06-14       Impact factor: 6.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.